Brief: Mbx Biosciences Says Phase 3 Trial Of Canvuparatide To Start In Q3 2026
11/01/2026 21:04
Jan 11 (Reuters) - MBX Biosciences Inc MBX.O: MBX BIOSCIENCES TO PROVIDE 2026 OUTLOOK AND BUSINESS UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE MBX BIOSCIENCES INC - PHASE 3 TRIAL OF CANVUPARATIDE TO START IN Q3 2026 MBX BIOSCIENCES INC - PHASE 1 DATA FOR MBX 4291 EXPECTED IN Q4 2026 MBX BIOSCIENCES INC - TWO NEW OBESITY CANDIDATES TO BE NOMINATED IN 2026 Source text: ID:nGNX6CLC51 Further company coverage: MBX.O ((Reuters.briefs@thomsonreuters.com;))
Recent news on MBX Biosciences
See all newsU.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
MBX Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: MBX Biosciences Announces Executive Leadership Transition To Support The Company’S Next Phase Of Growth
MBX Biosciences falls after executive shakeup
U.S. STOCKS ON THE MOVE-SpaceX, Tesla, Woodside Energy Group